Trial · NCT00449956

MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)

NCT00449956, Phase 3, Completed, Merck Sharp & Dohme LLC; results first posted 2009-05-29

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED). Trials, record NCT00449956. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00449956

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)
NCT number: NCT00449956
Status: Completed
Phases: Phase 3
Enrollment: 474 participants, actual
Lead sponsor: Merck Sharp & Dohme LLC
Conditions: Glaucoma
Interventions: dorzolamide hydrochloride (+) timolol maleate, Comparator: timolol maleate, Comparator: dorzolamide hydrochloride
First posted: 2007-03-21
Last updated: 2017-06-20
Results first posted: 2009-05-29

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Intraocular Pressure (IOP) From Baseline at 8 Weeks	8 weeks	Change from baseline to 8 weeks in Intraocular Pressure (IOP) assessed 2 hours after ocular instillation (at Hour 2)
Secondary	Percent Change From Baseline in Intraocular Pressure (IOP) at 8 Weeks	8 Weeks	Percent Change from baseline to 8 weeks in Intraocular Pressure (IOP) assessed 2 hours after ocular instillation (at Hour 2)
Secondary	Percent Change From Baseline in Outflow Pressure Reduction Rate at 8 Weeks	8 weeks	Percent Change from baseline to 8 weeks in Outflow Pressure Reduction Rate assessed 2 hours after ocular instillation (at Hour 2)

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Intraocular Pressure (IOP) From Baseline at 8 Weeks	8 weeks	Last observed value during the 8-week treatment period was used in the Full Analysis Set (FAS).	mmHg	LEAST_SQUARES_MEAN
SECONDARY	Percent Change From Baseline in Intraocular Pressure (IOP) at 8 Weeks	8 Weeks	Last observed value during the 8-week treatment period was used in the FAS.	Percent Change	LEAST_SQUARES_MEAN
SECONDARY	Percent Change From Baseline in Outflow Pressure Reduction Rate at 8 Weeks	8 weeks	Last observed value during the 8-week treatment period was used in the FAS.	Percent Change	LEAST_SQUARES_MEAN

Source ClinicalTrials.gov

Results by group9

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in Intraocular Pressure (IOP) From Baseline at 8 Weeks	MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)	-2.50	95% Confidence Interval -2.86 to -2.15	mmHg
Change in Intraocular Pressure (IOP) From Baseline at 8 Weeks	Timolol 0.5%	-1.82	95% Confidence Interval -2.33 to -1.31	mmHg
Change in Intraocular Pressure (IOP) From Baseline at 8 Weeks	Concomitant (Dorzolamide 1.0% / Timolol 0.5%)	-2.78	95% Confidence Interval -3.13 to -2.43	mmHg
Percent Change From Baseline in Intraocular Pressure (IOP) at 8 Weeks	MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)	-11.99	95% Confidence Interval -13.69 to -10.28	Percent Change
Percent Change From Baseline in Intraocular Pressure (IOP) at 8 Weeks	Timolol 0.5%	-8.74	95% Confidence Interval -11.18 to -6.30	Percent Change
Percent Change From Baseline in Intraocular Pressure (IOP) at 8 Weeks	Concomitant (Dorzolamide 1.0% / Timolol 0.5%)	-13.46	95% Confidence Interval -15.15 to -11.77	Percent Change
Percent Change From Baseline in Outflow Pressure Reduction Rate at 8 Weeks	MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)	23.47	95% Confidence Interval 20.07 to 26.88	Percent Change
Percent Change From Baseline in Outflow Pressure Reduction Rate at 8 Weeks	Timolol 0.5%	17.17	95% Confidence Interval 12.29 to 22.05	Percent Change
Percent Change From Baseline in Outflow Pressure Reduction Rate at 8 Weeks	Concomitant (Dorzolamide 1.0% / Timolol 0.5%)	26.75	95% Confidence Interval 23.37 to 30.12	Percent Change

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)	189
Overall Study	STARTED	Timolol 0.5%	92
Overall Study	STARTED	Concomitant (Dorzolamide 1.0% / Timolol 0.5%)	193
Overall Study	COMPLETED	MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)	179
Overall Study	COMPLETED	Timolol 0.5%	88
Overall Study	COMPLETED	Concomitant (Dorzolamide 1.0% / Timolol 0.5%)	184
Overall Study	NOT COMPLETED	MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)	10
Overall Study	NOT COMPLETED	Timolol 0.5%	4
Overall Study	NOT COMPLETED	Concomitant (Dorzolamide 1.0% / Timolol 0.5%)	9

Source ClinicalTrials.gov

Adverse events42

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Conjunctival hyperaemia	Eye disorders	MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)	3	189
other	Conjunctival hyperaemia	Eye disorders	Timolol 0.5%	1	92
other	Conjunctival hyperaemia	Eye disorders	Concomitant (Dorzolamide 1.0% / Timolol 0.5%)	4	193
other	Corneal epithelium defect	Eye disorders	MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)	2	189
other	Corneal epithelium defect	Eye disorders	Timolol 0.5%	2	92
other	Corneal epithelium defect	Eye disorders	Concomitant (Dorzolamide 1.0% / Timolol 0.5%)	5	193
other	Punctate keratitis	Eye disorders	MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)	3	189
other	Punctate keratitis	Eye disorders	Timolol 0.5%	0	92
other	Punctate keratitis	Eye disorders	Concomitant (Dorzolamide 1.0% / Timolol 0.5%)	6	193
other	Instillation site irritation	General disorders	MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)	13	189

1 to 10 of 42Source ClinicalTrials.gov

See all 42 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected
Total, all-cause mortality	MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)
Total, all-cause mortality	Timolol 0.5%
Total, all-cause mortality	Concomitant (Dorzolamide 1.0% / Timolol 0.5%)
Total, other adverse events	MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)	36
Total, other adverse events	Timolol 0.5%	12
Total, other adverse events	Concomitant (Dorzolamide 1.0% / Timolol 0.5%)	40
Total, serious adverse events	MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)	2
Total, serious adverse events	Timolol 0.5%	1
Total, serious adverse events	Concomitant (Dorzolamide 1.0% / Timolol 0.5%)	0

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
21735753	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00449956

GET https://conductscience.org/api/trials/v1/NCT00449956/events?page=2

API reference For AI assistants